Menu
NeuroGenesis is a clinical stage cellular therapy company focusing on innovative therapeutic approaches that target the underlying causes of central nervous system diseases such as progressive multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).
Leveraging advanced cellular therapy, the NG CELL™️ platform utilizes a proprietary subpopulation of bone marrow stem cells that are selected and enhanced to become remyelinating & regenerative biofactory cells—slowing and halting neurodegeneration in patients with debilitating neurological diseases.
Proprietary NG
CELL™ Platform
Clinical Pipeline
Cell Therapies for Demyelinating & Neurodegenerative Diseases
Promoting Regeneration
of Myelin & Neuronal Cells
NeuroGenesis is developing a cutting-edge approach to sustained delivery of unparalleled levels of remyelinating & regeneration proteins using the patient’s own stem cells. The technology is called NG CELL™. It entails collecting bone marrow from the patient. Then by utilizing a proprietary process, a unique subpopulation of bone marrow cells is identified and enhanced to remyelinating & regenerating biofactory cells (NG Cells). The NG Cells are expanded to tens of millions and injected directly into the spinal cord fluid, home-in on the damaged area, take up residence for up to three months and produce sustained, massive amounts of remyelinating & neuronal growth proteins in order to in-situ remyelinate, regenerate and repair.
The NG Cells have remyelinating, neuroprotective and neuro-regenerative properties. The cells can prevent neurons and oligodendrocytes from apoptosis via the release of remyelinating, regeneration and anti-apoptotic molecules (CNTF, BDNF, and others), and have anti-proliferative effects on microglial cells and astrocytes, resulting in the induction of a neuroprotective microenvironment. The neuroprotective and regenerative properties of NG Cells slow and stop patients from further neurodegeneration and improve their disability indices – so that people can get back to the lives they’re used to.
